Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2013

Lee Eunyoung, Keam Bhumsuk, Kim Dong-Wan, Kim Tae Min, Lee Se-Hoon, Chung Doo Hyun, Heo Dae Seog

Abstract excerpt

INTRODUCTION: Leptomeningeal carcinomatosis (LMC) from non-small-cell lung cancer (NSCLC) is a clinically important neurological complication in the era of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. METHODS: We retrospectively reviewed medical records of 25 EGFR TKI-treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood-Brain Barrier
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Meningeal Carcinomatosis

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 23804027
DOI: 10.1097/JTO.0b013e318294c8e8

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.PMID 23804027Read ↗

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).Semantic proximity Read ↗

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.Semantic proximity Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.Semantic proximity Read ↗

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.Semantic proximity Read ↗

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.Semantic proximity Read ↗

Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Leptomeningeal metastases in non-small-cell lung cancer.Semantic proximity Read ↗

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.Semantic proximity Read ↗

Treatment of leptomeningeal spread of NSCLC: a continuing challenge.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.